Inspire Investing LLC trimmed its holdings in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 9.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,544 shares of the company's stock after selling 2,832 shares during the quarter. Inspire Investing LLC's holdings in Encompass Health were worth $3,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also added to or reduced their stakes in the company. WPG Advisers LLC purchased a new stake in Encompass Health during the 1st quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Encompass Health by 749.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company's stock valued at $42,000 after purchasing an additional 367 shares during the last quarter. Park Place Capital Corp purchased a new stake in Encompass Health during the 2nd quarter valued at about $72,000. Arlington Trust Co LLC grew its stake in Encompass Health by 22.9% during the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after purchasing an additional 125 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Encompass Health by 19.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 720 shares of the company's stock valued at $73,000 after purchasing an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.
Encompass Health Stock Performance
NYSE EHC opened at $122.02 on Friday. The stock has a market capitalization of $12.29 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 2.15 and a beta of 0.93. Encompass Health Corporation has a twelve month low of $87.85 and a twelve month high of $127.86. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. The stock has a 50-day moving average of $122.73 and a 200 day moving average of $116.39.
Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share for the quarter. The company had revenue of $136.30 million during the quarter. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. Sell-side analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.
Encompass Health Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be issued a dividend of $0.19 per share. The ex-dividend date of this dividend is Wednesday, October 1st. This is an increase from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health's payout ratio is currently 14.87%.
Analysts Set New Price Targets
Several analysts have weighed in on the company. UBS Group boosted their price target on Encompass Health from $140.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, October 2nd. Bank of America boosted their price objective on Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday, September 10th. Weiss Ratings reissued a "buy (b+)" rating on shares of Encompass Health in a report on Wednesday. Truist Financial boosted their price objective on Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Finally, KeyCorp boosted their price objective on Encompass Health from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. Based on data from MarketBeat.com, Encompass Health currently has a consensus rating of "Buy" and a consensus target price of $139.86.
Check Out Our Latest Analysis on Encompass Health
Insider Activity at Encompass Health
In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the transaction, the executive vice president owned 18,846 shares of the company's stock, valued at $2,329,177.14. This represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.00% of the stock is owned by insiders.
Encompass Health Company Profile
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Stories
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Corporation (NYSE:EHC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
